AstraZeneca plc (AZN) Receives “Hold” Rating from Shore Capital

Shore Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Friday.

Several other research firms have also recently issued reports on AZN. Morgan Stanley reiterated an overweight rating and issued a GBX 5,600 ($72.70) target price on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.86) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Barclays PLC restated an overweight rating and set a GBX 6,000 ($77.89) price objective on shares of AstraZeneca plc in a research report on Monday, June 5th. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.00) price objective on shares of AstraZeneca plc in a research report on Monday, June 5th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of GBX 4,932.67 ($64.04).

Shares of AstraZeneca plc (LON AZN) traded down 0.76% on Friday, reaching GBX 4447.00. 1,614,494 shares of the company were exchanged. The firm’s 50 day moving average price is GBX 4,818.59 and its 200 day moving average price is GBX 4,863.31. The stock’s market capitalization is GBX 56.30 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was published by [[site]] and is the sole property of of [[site]]. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at [[permalink]].

The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be issued a GBX 68.90 ($0.89) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.

In related news, insider Nazneen Rahman bought 39 shares of the stock in a transaction on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.